Sarcoma lung surveillance study halted early: x-ray vs CT debate unresolved
NCT ID NCT01612481
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to compare chest X-ray and CT scans for detecting lung metastases in people who had surgery for high-grade soft tissue sarcoma. Only 11 patients were enrolled before the study was terminated early. The goal was to see which method better finds isolated, operable lung spread, but the small size limits what can be learned.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help determine the best way to monitor for lung cancer spread after sarcoma surgery, potentially reducing unnecessary scans and anxiety.
- What could go wrong
- The study was terminated early with only 11 participants, so results are very limited and may not provide clear answers. It is a small, early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG METASTASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Léon BERARD Center
Lyon, 69008, France
-
Oscar Lambret Center
Lille, 59020, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?
- Can a targeted pill stall advanced sarcomas?
- Can tracking tumor movement during radiation make treatment more precise?
- Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells